It’s like having 5x more fuel to keep your car running longer.
--- HEADER CONTENT --- HEADER CONTENT --- HEADER CONTENT ---
Important Safety Information    Prescribing Information
Rebinyn® Coagulation factor (Recombinant), Glycopegylated logo.
Rebinyn® is used to treat and control bleeding in adults and children with hemophilia B.
5x the fuel makes your car run 5x longer.
For factor IX therapy, 5x the half-life means 5x longer protection for hemophilia B treatment. With a half-life that’s 5x longer than BeneFIX®,a where can Rebinyn® take you?
 Explore Now 
aBased upon a phase 1 study comparing 25, 50, and 100 IU/kg doses of Rebinyn® to a 50 IU/kg dose of standard half-life rFIX in 7 adults and a 50 IU/kg dose of plasma-derived FIX in 8 adults. For Rebinyn®, estimated average FIX activity is adjusted to a dose of 50 IU/kg.
Rebinyn® achieved an 83-hour average half-life in adults (~3.5 days)b
bIn two phase 3 studies, factor levels were evaluated for 1 week after the first dose of Rebinyn® 40 IU/kg. The average levels after 7 days were 16.8% in 6 adults, 14.6% in 3 adolescents, 10.9% in 13 children ages 7 to 12 years, and 8.4% in 12 children up to age 6 years.
• Rebinyn® is not used for routine prophylaxis or for immune tolerance therapy
• Animals given repeat doses of Rebinyn® showed Polyethylene Glycol (PEG) inside cells lining blood vessels in the choroid plexus, which makes the fluid that cushions the brain. The potential human implications of these animal tests are unknown
Selected Important Safety Information
What is the most important information I need to know about Rebinyn®?
• Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn®.
Who should not use Rebinyn®?
Do not use Rebinyn® if you:
• are allergic to Factor IX or any of the other ingredients of Rebinyn®.
• are allergic to hamster proteins.
Indications and Usage
What is Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated?
Rebinyn® is an injectable medicine used to replace clotting Factor IX that is missing in patients with hemophilia B. Rebinyn® is used to treat and control bleeding in people with hemophilia B. Your healthcare provider may give you Rebinyn® when you have surgery. Rebinyn® is not used for routine prophylaxis or for immune tolerance therapy.
Important Safety Information
What is the most important information I need to know about Rebinyn®?
• Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center. Carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing Rebinyn®.
Who should not use Rebinyn®?
Do not use Rebinyn® if you:
• are allergic to Factor IX or any of the other ingredients of Rebinyn®.
• are allergic to hamster proteins.
What should I tell my healthcare provider before using Rebinyn®?
Tell your healthcare provider if you:
• have or have had any medical conditions.
• take any medicines, including non-prescription medicines and dietary supplements.
• are nursing, pregnant, or plan to become pregnant.
• have been told you have inhibitors to Factor IX.
How should I use Rebinyn®?
• Rebinyn® is given as an infusion into the vein.
• Call your healthcare provider right away if your bleeding does not stop after taking Rebinyn®.
• Do not stop using Rebinyn® without consulting your healthcare provider.
What are the possible side effects of Rebinyn®?
• Common side effects include swelling, pain, rash or redness at the location of the infusion, and itching.
• Call your healthcare provider right away or get emergency treatment right away if you get any of the following signs of an allergic reaction: hives, chest tightness, wheezing, difficulty breathing, and/or swelling of the face.
• Tell your healthcare provider about any side effect that bothers you or that does not go away.
• Animals given repeat doses of Rebinyn® showed Polyethylene Glycol (PEG) inside cells lining blood vessels in the choroid plexus, which makes the fluid that cushions the brain. The potential human implications of these animal tests are unknown.
Please click here for Prescribing Information.
Rebinyn® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500.
UNSUBSCRIBE NOTICE
If you no longer want to receive communications from Novo Nordisk, the sponsor of this content, click here to unsubscribe. You also may call Novo Nordisk at 1.877.744.2579 or send a letter that includes your full contact information (e.g. name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see the Privacy Statement.
Rebinyn® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2020 Novo Nordisk  All rights reserved.  US20REB00015  August 2020
Novo Nordisk logo.
Novo Nordisk logo.
--- FOOTER CONTENT --- FOOTER CONTENT --- FOOTER CONTENT ---